Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2028-09-01
Target enrollment:
Participant gender:
Summary
The main goal of this first in human (FIH) study is to learn about the safety and dosing of
GS-0201 when given alone or in combination with sacituzumab govitecan (SG) in participants
with advanced solid tumors.
The primary objectives of this study are to:
- To assess the safety and tolerability of GS-0201 as monotherapy and in combination with
SG in participants with selected advanced solid tumors
- To identify the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D)
of GS-0201 as monotherapy and the MTD and/or the RP2D and dosing schedule of GS-0201 in
combination with SG in participants with selected advanced solid tumors